Features of pathogenetic mechanisms of protein-energy wasting development in patients with chronic kidney disease stage 5D


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. evaluation of the complex contribution of myostatin (mstn) and protein kinase-b (Akt) to the development of protein-energy malnutrition in patients with chronic kidney disease (CKD) receiving programmed hemodialysis. material and methods. the study involved 80 patients with stage 5D ckd. all subjects underwent general clinical and biochemical examination; the blood serum of mstn and akt levels were determined using enzyme-linked immunosorbent assay, and the severity of protein-energy malnutrition (рем) was assessed using a complex technique. results. the prevalence of pem was 90%. the relationships between the markers of muscle tissue metabolism mstn and akt with iron deficiency, hyperparathyroidism, vitamin D deficiency, as well as with indicators of systemic inflammation were determined. to assess the effect of the mstn/akt signaling pathway on the development of pem in hemodialysis patients, an original muscle tissue catabolism index (MTCi) was developed. conclusion. mstn and akt make a significant contribution to the development of pem in patients with stage 5D ckd. the proposed mtci is promising tool in assessing the severity of not only pem, but also sarcopenia, which is of research interest

Full Text

Restricted Access

About the authors

A. S Kuzyarova

ООО Dialysis Center Nephros-Don

Email: lina.kuzyarova@mail.ru
Cand. Sci. (Med.), Nephrologist Rostov-on-Don, Russia

M. Z Gasanov

Rostov State Medical University

Email: mitkhat@mail.ru
Cand. Sci. (Med.), Associate Professor at the Department of Internal Diseases № 1 Rostov-on-Don, Russia

M. M Batyushin

Rostov State Medical University

Email: batjushin-m@rambler.ru
Dr. Sci. (Med.), Professor at the Department of Internal Diseases №. 2, Head of the Nephrology Department Rostov-on-Don, Russia

K. R Bogomolova

Rostov State Medical University

Email: bowsaw@mail.ru
4th-year student of the Faculty of Pediatrics Rostov-on-Don, Russia

I. H Adamokova

Rostov State Medical University

Email: irina_adamokova@mail.ru
5th-year student of the Faculty of Pediatrics Rostov-on-Don, Russia

References

  1. Koppe L., Fouque D., Kalantar-Zadeh K. Kidney cachexia or protein-energy wasting in chronic kidney disease: facts and numbers. J. Cachexia Sarcopenia Muscle. 2019;10(3):479-484. doi: 10.1002/jcsm.12421.
  2. Ветчинникова О.Н., Пичугина И.С. Белково-энергетическая недостаточность у пациентов с хронической болезнью почек на диализной терапии. Учебное пособие. М., 2015. 55 с.
  3. Смирнов А.В., Голубев Р.В., Коростелева Н.Ю., Румянцев А.Ш. Снижение физической работоспособности у больных, получающих заместительную почечную терапию: фокус на саркопению. Нефрология. 2017;21(4):9-29
  4. Mak R.H., Ikizler A.T., Kovesdy C.P., et al. Wasting in chronic kidney disease. J. Cachexia Sarcopenia Muscle. 2011;2(1):9-25.
  5. Schardong J., Marcolino M.Z, Plentz R.M. Muscle Atrophy in Chronic Kidney Disease. Adv. Exp. Med. Biol. 2018. In the book Atrophy of muscles. P. 393-412. Doi: 10.1007 / 978-981-13-1435-3_18.
  6. Kuzyarova A.S., Gasanov M.ZZ., Batyushin M.M., et al. The role of myostatin and protein kinase-в in the development of protein-energy wasting in patients with end-stage renal disease on hemodialysis. Georgian Med. News. 2019;4(289):47-50.
  7. Гасанов М.З. Молекулярные аспекты патогенеза саркопении у пациентов с хронической болезнью почек: интегративная роль mTOR. Нефрология. 2018;22(5):9-16.
  8. Sharma M., McFarlane C., Kambadur R., et al. Myostatin: Expanding horizons. IUBMB Life. 2015;67(8):589-600.
  9. Thomas S., Mitch W. Mechanisms stimulating muscle wasting in chronic kidney disease: the roles of the ubiquitin-proteasome system and myostatin. Clin. Exp. Nephrol. 2013;17(2):174-82.
  10. Der-Sheng Han 1, Yung-Ming Chen, Sen-Yung Lin., et al. Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis. Clin. Endocrinol. (Otf). 2011; 75(6):857-63. Doi: 10.1111/j. 1365-2265.2011.04120.x.
  11. Wang X.H., Mitch W.E. Mechanisms of muscle wasting in chronic kidney disease. Nat. Rev. Nephrol. 2014;10(9):504-16. Doi.org/10.1038/nrneph.2014.112.
  12. Delanaye P., Bataille S., Quinonez K., et al. Myostatin and Insulin-Like Growth Factor 1 Are Biomarkers of Muscle Strength, Muscle Mass, and Mortality in Patients on Hemodialysis. J. Ren. Nutr. 2019;29(6):511-20. Doi: 10.1053/j. jrn.2018.11.010.
  13. Яковенко А.А., Лаврищева Ю.В., Румянцев А.Ш. Новые возможности скрининга белково-энергетической недостаточности у пациентов, получающих лечение программным гемодиализом. Нефрология и диализ. 2019;21(2):243- 49.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies